NCT01260844View on ClinicalTrials.gov

Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

PHASE1WithdrawnINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2011

Conditions
Moderate to Severe Plaque Psoriasis
Interventions
DRUG

briakinumab

single dose briakinumab and 2 doses of CYP substrates

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY